radiglip-m 500 mg + 50 mg tableta recubierta
ddm biohealth peru s.a.c. - tableta recubierta - por mililitro ; clorhidrato de metformina 500.000000 mg; sitagliptina 62.030000 mg; - metformina y sitagliptina
diagliptina met comprimido recubierto
roemmers - comprimido recubierto - sitagliptina 50 mg + metformina 850 mg comprimido
janumet 50mg/850mg comprimido recubierto
merck sharp & dohme peru s.r.l. - droguerÍa - comprimido recubierto - por comprimido - - metformina y sitagliptina
janumet 50/500mg comprimido recubierto
merck sharp & dohme peru s.r.l. - comprimido recubierto - por comprimido - metformina y sitagliptina
janumet 50mg/1000mg comprimido recubierto
merck sharp & dohme peru s.r.l. - comprimido recubierto - por comprimido - metformina y sitagliptina
metformina clorhidrato+sitagliptina 500mg+50mg tableta recubierta
ddm biohealth peru s.a.c. - tableta recubierta - por tableta; clorhidrato de metformina 500.000000 mg; sitagliptina 62.030000 mg; - metformina y sitagliptina
isoniazida 100 mg
por tableta; isoniazida 100.000000 mg; - metformina y sitagliptina
sitrax-m ® 50/1000 50 mg + 1000 mg tableta recubierta
seven pharma s.a.c. - tableta recubierta - por tableta - metformina y sitagliptina
metfo 750 750 mg capsula de liberacion prolongada
diphasac sociedad anonima cerrada - capsula de liberacion prolongada - por tableta - metformina y sitagliptina
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.